Search results
Results From The WOW.Com Content Network
However, I think it's a good choice for income investors, with its forward dividend yield of nearly 4% and an improving outlook. Should you invest $1,000 in Viatris right now? Before you buy stock ...
This page was last edited on 19 February 2025, at 23:44 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Until recently, Viatris (NASDAQ:VTRS) was considered a value play among drug stocks. But after its recent earnings report, and announced sale of a key asset? The generic drug maker has been deemed ...
Viatris expects full-year earnings in the range of $2.56 to $2.71 per share, with revenue in the range of $14.6 billion to $15.1 billion. ... Access a Zacks stock report on VTRS at https://www ...
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn , a legacy division of Pfizer , on November 16, 2020.
The stock of Viatris (NAS:VTRS, 30-year Financials) is believed to be modestly undervalued, according to GuruFocus Value calculation.
In 1976 the stock moved to the National Association of Securities Dealers Automated Quotations . Their final stock move was in 1986, when their stock became available for trade on the New York Stock Exchange under the ticker symbol MYL. Prior to the Viatris combination, the stock was traded on the NASDAQ.
Viatris also reaffirmed its full-revenue revenue forecast to the range of $15.5 billion to $16 billion, compared to analysts' estimates of $15.60 billion. Excluding items, the company reported a ...